文献速递乳腺MR

新辅助化疗期间肿瘤缩小模式与低级别Luminal早期乳腺癌预后相关

Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer.
PubMed 文献 · Radiology · 2017-07-24

回顾性分析2000年至2012年同一机构接受新辅助化疗的低级别Luminal乳腺癌患者,发现化疗期间MRI显示向心性缩小模式与无病生存和总生存独立相关,验证集显示向心性缩小组无病生存72.8个月 vs 非向心性缩小组56.0个月(P ≤ .001)。

要点

  • 新辅助化疗期间MRI评估的向心性缩小模式是低级别Luminal乳腺癌预后的独立因素。
  • 验证集中向心性缩小组无病生存72.8个月,非向心性缩小组为56.0个月(P ≤ .001)。
  • 向心性缩小组中位总生存80.6个月,非向心性缩小组为65.0个月(P = .004)。

核心结论

  • 新辅助化疗期间MRI显示的向心性缩小模式与低级别Luminal乳腺癌预后有唯一显著的独立关联。

研究设计与样本

  • 回顾性研究,开发集183例、验证集121例低级别Luminal乳腺癌患者,均来自同一机构,接受新辅助化疗及MRI评估。

关键影像表现/征象

  • MRI显示的肿瘤缩小模式分为向心性缩小(CS)和非向心性缩小(non-CS)两类。

诊断标准与关键数值

  • 低级别Luminal乳腺癌定义为激素受体阳性、人表皮生长因子受体2阴性且核分级为1或2级。
  • 验证集向心性缩小组无病生存72.8个月(95%CI:69.9,75.6个月)vs 非向心性缩小组56.0个月(95%CI:49.1,62.9个月),P ≤ .001。
  • 验证集向心性缩小组中位总生存80.6个月(95%CI:79.3,81.8个月)vs 非向心性缩小组65.0个月(95%CI:60.1,69.8个月),P = .004。
  • 多因素分析显示向心性缩小模式与无病生存(开发集P = .001,验证集P = .007)和总生存(开发集P = .009,验证集P = .037)独立相关。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the association between tumor shrinkage patterns shown with magnetic resonance (MR) imaging during neoadjuvant chemotherapy (NAC) and prognosis in patients with low-grade luminal breast cancer. Materials and Methods This retrospective study was approved by the institutional review board and informed consent was obtained from all subjects. The low-grade luminal breast cancer was defined as hormone receptor-positive and human epidermal growth factor receptor 2-negative with nuclear grades 1 or 2. The patterns of tumor shrinkage as revealed at MR imaging were categorized into two types: concentric shrinkage (CS) and non-CS. Among 854 patients who had received NAC in a single institution from January 2000 to December 2009, 183 patients with low-grade luminal breast cancer were retrospectively evaluated for the development set. Another data set from 292 patients who had received NAC in the same institution between January 2010 and December 2012 was used for the validation set. Among these 292 patients, 121 patients with low-grade luminal breast cancer were retrospectively evaluated. Results In the development set, the median observation period was 67.9 months. Recurrence was observed in 31 patients, and 16 deaths were related to breast cancer. There were statistically significant differences in both the disease-free survival (DFS) and overall survival (OS) rates between patterns of tumor shrinkage (P < .001 and P < .001, respectively). Multivariate analysis demonstrated that the CS pattern had the only significant independent association with DFS (P = .001) and OS (P = .009) rate. In the validation set, the median follow-up period was 56.9 months. Recurrence was observed in 20 patients (16.5%) and eight (6.6%) deaths were related to breast cancer. DFS rate was significantly longer in patients with the CS pattern (72.8 months; 95% confidence interval [CI]: 69.9, 75.6 months) than in those with the non-CS pattern (56.0 months; 95% CI: 49.1, 62.9 months; P ≤ .001). The CS pattern was associated with an excellent prognosis (median OS, 80.6 months; 95% CI: 79.3, 81.8 months vs 65.0 months; 95% CI: 60.1, 69.8 months; P = .004). Multivariate analysis demonstrated that the CS pattern had the only significant independent association with DFS (P = .007) and OS (P = .037) rates. Conclusion The CS pattern as revealed at MR imaging during NAC had the only significant independent association with prognosis in patients with low-grade luminal breast cancer. © RSNA, 2017.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Fukada I, Araki K, Kobayashi K, et al. Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer. Radiology. 2017. PMID: 28737968. doi:10.1148/radiol.2017161548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。